Evidence map›Paper›PMID 32502272›Full record

ArticleThe Journal of infectious diseases2021

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.

Andrew Hastie, Grégory Catteau, Adaora Enemuo, Tomas Mrkvan, Bruno Salaun, Stephanie Volpe, Jan Smetana, Lars Rombo, Tino Schwarz, Karlis Pauksens and 3 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02735915 (Long Term Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Subunit), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02735915 phase3completednot on this map

Long Term Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine 1437173A and Assessment of Re-vaccination With 2 Additional Doses, in Healthy Subjects Aged 60 Years of Age and Older

TypeinterventionalSponsorGlaxoSmithKlineRan2016 to 2018Enrolled70ConditionsHerpes ZosterArmsHerpes Zoster Vaccine GSK1437173A
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Herpes zoster infection in patients with inflammatory bowel disease.The Korean journal of internal medicine · 2025
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Andrew HastieGSK, Rockville, Maryland, USA.
Grégory CatteauGSK, Wavre, Belgium.
Adaora EnemuoGSK, Rockville, Maryland, USA.
Tomas MrkvanGSK, Wavre, Belgium.
Bruno SalaunGSK, Rixensart, Belgium.
Stephanie VolpeGSK, Wavre, Belgium.
Jan SmetanaFaculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic.
Lars RomboCentre for Clinical Research, Eskilstuna, Sweden.
Tino SchwarzKlinikum Wuerzburg Mitte, Standort Juliusspital, Wuerzburg, Germany.
Karlis PauksensDepartment of Infectious Diseases, Uppsala University Hospital, Uppsala, Sweden.
Caroline HervéUCB Pharma, Braine-L'Alleud, Belgium.
Adriana BastidasMithra Pharmaceuticals, Flémalle, Belgium.
Anne SchuindGSK, Rockville, Maryland, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe adjuvanted recombinant zoster vaccine (RZV) is highly immunogenic and efficacious in adults ≥50 years of age. We evaluated (1) long-term immunogenicity of an initial 2-dose RZV schedule, by following up adults vaccinated at ≥60 years of age and by modeling, and (2) immunogenicity of 2 additional doses administered 10 years after initial vaccination.

methodsPersistence of humoral and cell-mediated immune (CMI) responses to 2 initial RZV doses was assessed through 10 years after initial vaccination, and modeled through 20 years using a Piecewise, Power law and Fraser model. The immunogenicity and safety of 2 additional RZV doses were also evaluated.

resultsSeventy adults were enrolled. Ten years after initial vaccination, humoral and CMI responses were approximately 6-fold and 3.5-fold, respectively, above those before the initial vaccination levels. Predicted immune persistence through 20 years after initial vaccination was similar across the 3 models. Sixty-two participants (mean age [standard deviation], 82.6 [4.4] years) received ≥1 additional RZV dose. Strong anamnestic humoral and CMI responses were elicited by 1 additional dose, without further increases after a second additional dose.

conclusionsImmune responses to an initial 2-dose RZV course persisted for many years in older adults. Strong anamnestic immune responses can be induced by additional dosing 10 years after the initial 2-dose course. CLINICAL TRIALS REGISTRATION: NCT02735915.

Indexed as

Immunogenicity, VaccineAdjuvants, ImmunologicAgedAged, 80 and overHerpesvirus 3, HumanHerpes ZosterHerpes Zoster VaccineHumansMiddle AgedVaccinationVaccines, SyntheticAdjuvants, ImmunologicHerpes Zoster VaccineVaccines, Syntheticadjuvanted recombinant zoster vaccineherpes zosterpersistence of immune responsesafety

Identifiers

PMID32502272
PMCPMC8672743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.